Skip to main content

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Finance Veteran as Newest Business Advisory Board Member

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine-learning capabilities, its extensive biorepository of tumor samples, and its Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, has appointed a new member to its business advisory board. The company announced that biopharmaceutical finance veteran Andrew Einhorn will be serving in the capacity. Cofounder and CFO of Oceana Therapeutics Inc., Esprit Pharma Inc. and ESP Pharma Inc., Einhorn brings an impressive wealth of experience to his new role. Nothing that the AI market for early drug discovery is growing rapidly and that POAI is uniquely positioned to be a leader in the emerging industry, Einhorn stated that he looks forward to helping the company achieve its full operational and financial potential. Einhorn currently works at Danforth Advisors providing financial advisory services to a range of public and privately held companies. He also has experience in investment banking and capital markets, managing debt, equity and structured financing transactions with institutional investors. “Andrew Einhorn brings a wealth of senior financial leadership experience in the biopharmaceutical industry to our Business Advisory Board, and I am very pleased that he has agreed to join,” said Predictive Oncology CEO Raymond F. Vennare in the press release. “As our momentum continues to accelerate, Andrew’s insights, expertise and perspectives will be invaluable in our persistent efforts to deliver unique solutions to our drug development partners while creating lasting value for our shareholders.”

To view the full press release, visit

About Predictive Oncology Inc.

Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence (“AI”) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. With PEDAL and the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based, drug-discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.